• Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors
  • Resveratrol science
  • Policies
Jupiter Orphan Therapeutics
  • Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors
  • Resveratrol science
  • Policies

Jupiter Orphan Therapeutics, Inc.

JOT is a Clinical stage CNS focused company. JOT's Platform product, JOTROL™, is applicable to several rare diseases, such as Ataxia's, LSD's and Mitochondrial Diseases. Non-dilutive financing, Phase I trial financing received from NIA, makes the approach to Alzheimer’s Disease very attractive and will be developed in parallel with the rare disease applications.

Proudly powered by Weebly
  • Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors
  • Resveratrol science
  • Policies